Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Andrew Ostrenga"'
Autor:
L. Lee Dupuis, Betsy Poon, Andrew Ostrenga, Scott E. Walker, Shirley Law, JoEllen Weilnau, M Petrea Cober, Pacita Sales, Karen Lingertat-Walsh
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:78-87
Background Temozolomide oral suspension is not commercially available. Objective To evaluate the stability of three temozolomide 10 mg/mL suspensions prepared in Oral Mix SF® in three container types stored at 4°C and 23°C. Methods Using commercia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22c16643bc012fe247d0a4a7c9b87d94
https://doi.org/10.1177/1078155220914349
https://doi.org/10.1177/1078155220914349
Autor:
Wei Xue, Jennifer O. Black, Andrew Ostrenga, Simon C. Kao, Barry L. Shulkin, James R. Anderson, R. Lor Randall, Rajkumar Venkatramani, Suzanne L. Wolden, Dolores Lopez-Terrada, Alberto S. Pappo, Sheri L. Spunt
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 35
J Clin Oncol
J Clin Oncol
PURPOSE Synovial sarcoma (SS) is the second most common malignant soft tissue tumor in children. ARST0332 evaluated a risk-based treatment strategy for young patients with soft tissue sarcoma designed to limit therapy for low-risk (LR) disease and to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f739b27bf97ada1362acb9704f7d5411
https://escholarship.org/uc/item/62b5r8q0
https://escholarship.org/uc/item/62b5r8q0
Autor:
Aaron R. Weiss, Yen-Lin Chen, Thomas Scharschmidt, Wei Xue, Zhengya Gao, Jennifer O. Black, Julie Fanburg-Smith, Eduardo Zambrano, Edwin Choy, Jessica L. Davis, Mark Kayton, Lynn Million, Scott H. Okuno, Andrew Ostrenga, R. Lor Randall, Stephanie Terezakis, Rajkumar Venkatramani, Dian Wang, Douglas S. Hawkins, Sheri L. Spunt
Publikováno v:
Journal of Clinical Oncology. 40:11504-11504
11504 Background: Pazopanib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity in advanced soft tissue sarcoma. ARST1321 was a phase II study designed to compare the near complete pathologic response rate (≥ 90% necrosis) following p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5143cde986da1d6f01d867edbc94b207
https://doi.org/10.1200/jco.2022.40.16_suppl.11504
https://doi.org/10.1200/jco.2022.40.16_suppl.11504
Autor:
Barry L. Shulkin, Aaron R. Weiss, William H. Meyer, Mark L. Kayton, Ruth P. Lim, Sandy Kessel, Odion Binitie, Eduardo Zambrano, Edwin Choy, R. Lor Randall, Thomas J. Scharschmidt, Jing Tian, Yueh Yun Chi, Joel I. Sorger, Simon C. Kao, Andrew Ostrenga, Mary Schlapkohl, Jennifer O. Black, Ethan A. Smith, James R. Anderson, Marguerite T. Parisi, Jessica L. Davis, Mark A. Rosen, Dian Wang, Yen-Lin Chen, Daniel A. Pryma, Stephanie A. Terezakis, Justin Davis, Julie C. Fanburg-Smith, Andrea Hayes-Jordan, Robin Arens, Douglas S. Hawkins, Sheri L. Spunt, Scott H. Okuno, Lynn Million
Publikováno v:
The Lancet. Oncology, vol 21, iss 8
Lancet Oncol
Lancet Oncol
BackgroundOutcomes for children and adults with advanced soft tissue sarcoma are poor with traditional therapy. We investigated whether the addition of pazopanib to preoperative chemoradiotherapy would improve pathological near complete response rate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::160f3b470abf0b52c6e50289de46e174
https://escholarship.org/uc/item/9ht1j070
https://escholarship.org/uc/item/9ht1j070
Publikováno v:
Critical Care Medicine. 48:271-271
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f322fd7aadd5a96cb397466e54950eaf
https://doi.org/10.1097/01.ccm.0000626064.73725.72
https://doi.org/10.1097/01.ccm.0000626064.73725.72
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 74(11)
Purpose A retrospective study was conducted to compare various methods of measuring serum creatinine (SCr) values for use in pediatric renal function assessments, including a method aligned with a recently implemented national SCr testing standard. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90e8d09d56b1be62094bcd465d75e639
https://pubmed.ncbi.nlm.nih.gov/28546304
https://pubmed.ncbi.nlm.nih.gov/28546304
Autor:
Mark Kayton, Douglas S. Hawkins, Joel I. Sorger, Yueh-Yun Chi, Jing Tian, Scott H. Okuno, Andrew Ostrenga, Julie Fanburg-Smith, Jessica L. Davis, Dian Wang, Lynn Million, Thomas J. Scharschmidt, Yen-Lin Chen, Aaron R. Weiss, Eduardo Zambrano, Sheri L. Spunt, R. Lor Randall, Jennifer O. Black, Stephanie A. Terezakis, Edwin Choy
Publikováno v:
Journal of Clinical Oncology. 37:11002-11002
11002 Background: Pazopanib is a multi-targeted tyrosine kinase inhibitor with activity in advanced soft tissue sarcoma. ARST1321 is a phase II study designed to compare the near complete pathologic response rate (≥ 90% necrosis) of preoperative ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61fb12b032a505a05e49e53291afa05c
https://doi.org/10.1200/jco.2019.37.15_suppl.11002
https://doi.org/10.1200/jco.2019.37.15_suppl.11002
Autor:
Dian Wang, Douglas S. Hawkins, Yueh-Yun Chi, R.L. Randall, Mark Kayton, Eduardo Zambrano, Yen-Lin Chen, Sheri L. Spunt, Andrew Ostrenga, Jennifer M. Black, Thomas J. Scharschmidt, Aaron R. Weiss, Scott H. Okuno, Simon C. Kao, Stephanie A. Terezakis, Edwin Choy
Publikováno v:
Journal of Clinical Oncology. 37:11070-11070
11070 Background: Pazopanib is a tyrosine kinase inhibitor approved globally for advanced soft tissue sarcomas. The dose finding phase of this cooperative group trial assessed the dose limiting toxicities (DLT) and the maximally tolerated dose (MTD)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::977914ea34347e5148357289c2b52e87
https://doi.org/10.1200/jco.2019.37.15_suppl.11070
https://doi.org/10.1200/jco.2019.37.15_suppl.11070
Publikováno v:
Journal of alternative and complementary medicine (New York, N.Y.). 21(11)
To examine the prevalence and modalities of complementary and alternative medicine (CAM) use in children with cancer and sickle cell disease; the reasons for use of CAM; and the use of CAM before, during, and after treatment in children with cancer.T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20c50dabd95a7f419004fbd5484e7d13
https://pubmed.ncbi.nlm.nih.gov/26302151
https://pubmed.ncbi.nlm.nih.gov/26302151
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 20(3)
Purpose The increased use of oral chemotherapy for the treatment of cancer introduces new challenges for patients and caregivers. Among them are the ability to swallow oral solid dosage forms, the proper administration of the agents and the safe-hand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69a68c95329fe87a0b6e6fbf24951be2
https://pubmed.ncbi.nlm.nih.gov/23748870
https://pubmed.ncbi.nlm.nih.gov/23748870